“Korea biosimilars are very successful, but manufacturers still need to work on dependency”

“Korean biosimilar manufacturers must raise dependent capability for them not to rely on foreign partners in a long-term. In order to do so, they must fully understand the global market and have enough investments.”

Murray Aitken, Head of IMS Institute for Health Information, stressed securement of own capability as a key to success for Korean biosimilar manufacturers.

The head, who recently ...